Underlying Mechanisms for Distant Metastasis - Molecular Biology

Slides:

Advertisements

Similar presentations

Medical Genetics & Genomics Guri Tzivion, PhD Extension 506 BCHM 560: January 2015 Windsor University School of Medicine.

Advertisements

Clinical developmentDiscovery Typical development timeline Typically – 8 yearsTypically 7 years.

In vivo animal model studies in biological science 1.Cancer 2. Neuroscience 1.Cancer research 2. Neuroscience.

Cytoplasmic Signaling Circuitry Programs Many of the Traits of Cancer

Student Research Interest HER2 Receptor Signaling in Breast Cancer Cells Marc Y. Fink Biomedical Sciences LIU-Post.

Biological and Molecular Targeted Therapy for HHC

Advanced Cancer Topics Journal Review 4/16/2009 AD.

The c-Met receptor contributes to motility and invasion in high grade STS; a potential therapeutic target Sarah E. Myers, Theresa G. Nguyen, Quan-Sheng.

Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.

Aiming at the Wrong Target? Discussion of Abstracts CRA3507 (Alberts) and 3508 (Goldberg) Louis M. Weiner, MD Lombardi Comprehensive Cancer Center Georgetown.

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

1 Hepatocellular Carcinoma Overview of Hepatocellular Carcinoma Epidemiology.

A Discussion on Biologic Agents in Gastric Cancer Treatment Yoon-Koo Kang, MD Professor of Medicine Asan Medical Center University of Ulsan College of.

Are macrophages interesting targets for anti-cancer therapy?

Samsung Genome Institute Samsung Medical Center

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Cell Physiol Biochem 2017;42:2582– DOI: /

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Control of Gene Expression

Med Princ Pract 2016;25(suppl 2): DOI: /

Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small.

Volume 76, Issue 9, Pages (November 2009)

Volume 59, Issue 5, Pages (November 2013)

Figure 2 Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis Figure 2 | Crosstalk between TGF-β/Smad and other pathways in tissue fibrosis.

David Largaespada, Nancy Ratner Cancer Cell

Connecting COX-2 and Wnt in cancer

Miriam Marqués, Francisco X. Real European Urology

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Latest Advances in Chemotherapeutic, Targeted, and Immune Approaches in the Treatment of Metastatic Melanoma Darshil J. Shah, MD, MPH, Roxana S. Dronca,

Figure 1 A schematic representation of the HER2 signalling pathway

Biology and Clinical Applications of Pancreatic Cancer Stem Cells

BDNF and insulin signaling pathways activated by phytochemicals.

Schematic representation of main EGFR-TKIs resistance mechanisms.

Targeted Therapies in Melanoma: Translational Research at Its Finest

Volume 29, Issue 3, Pages (March 2016)

The pathway signalling starts with the binding of insulin or growth factors to insulin receptors. The pathway signalling starts with the binding of insulin.

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

Caught in the Akt: Regulation of Wnt Signaling in the Intestine

Volume 25, Issue 4, Pages (December 2018)

Figure 5 The mechanism underlying epithelial-to-mesenchymal

Volume 59, Issue 5, Pages (November 2013)

Inflammation, Epithelial to Mesenchymal Transition, and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Kostyantyn Krysan, PhD,

Inhibition of mammalian target of rapamycin: Two goals with one shot?

Taru Muranen, Funda Meric-Bernstam, Gordon B. Mills Cancer Cell

The Ying and Yang of Bacterial Signaling in Necrotizing Enterocolitis

Vascular Endothelial Growth Factor (VEGF) Pathway

FGFR Signaling as a Target for Lung Cancer Therapy

Volume 76, Issue 9, Pages (November 2009)

Met as a therapeutic target in HCC: Facts and hopes

Targeting STAT3 in hepatocellular carcinoma: Sorafenib again…

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

SRC and STAT Pathways Journal of Thoracic Oncology

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

Cancer and Inflammation: An Aspirin a Day Keeps the Cancer at Bay

A Wnt Survival Guide: From Flies to Human Disease

Platelet-derived growth factor (PDGF) signalling pathway.

Fig. 3. Inactivation of the Wnt/β-catenin signaling pathway inhibited cell proliferation and induced apoptosis in A549 and SPC-A-1 cells. Inactivation.

GPC5 Gene and Its Related Pathways in Lung Cancer

Friends with Benefits: Microenvironmental NRG1β and HGF Mediate HER2-Targeted Resistance in L-HER2+ and HER2E Breast Cancer Sarah B. Crist, Cyrus M.

Schematic representation of signaling pathways modulated by PKD1 in cancer. Schematic representation of signaling pathways modulated by PKD1 in cancer.

Volume 119, Issue 4, Pages (October 2000)

Volume 4, Issue 4, Pages (April 2009)

Signalling pathways and involved entities that are unravelling experimental therapeutic targets for TNBC. Depicted molecular landscape of TNBC confers.

Single-Dose Neoadjuvant AKT Pathway Inhibitor Reduces Growth of Hepatocellular Carcinoma after Laser Thermal Ablation in a Small Animal Model Neoadjuvant PI3K/mTOR/AKT inhibitor prior.

Figure 4 Molecular signalling and immunological

Expression of versican promoted breast cancer cell self-renewal through enhanced EGFR/AKT/GSK-3β (S9P) signals. Expression of versican promoted breast.

High nuclear β-catenin levels confer resistance to AKT inhibition and coordinates with increased nuclear FOXO3a to promote metastasis in colon cancer.

Connections between insulin/insulin-like growth factor 1 signaling and metabolic pathways in tumor cells. Connections between insulin/insulin-like growth.

Cell-autonomous mechanisms of resistance to targeted therapies involving the HGF/MET axis. Cell-autonomous mechanisms of resistance to targeted therapies.

Tackling Resistance to PI3K Inhibition by Targeting the Epigenome

Presentation transcript:

Underlying Mechanisms for Distant Metastasis - Molecular Biology Visc Med 2017;33:11-20 - DOI:10.1159/000454696 Fig. 1. Invasion-metastasis cascade (modified from Valastyan et al. [6]). © 2017 S. Karger AG, Basel

Underlying Mechanisms for Distant Metastasis - Molecular Biology Visc Med 2017;33:11-20 - DOI:10.1159/000454696 Fig. 2. EGFR signaling: key components of the RAS/RAF/MEK/ERK and PI3K/Akt/mTOR signaling pathways and their influence on the metastatic cascade. An activated receptor tyrosine kinase (e.g. EGFR) starts both cascades resulting in the activation of the downstream effectors Akt, mTORC-1/-2, and ERK. Available therapeutics targeting these signaling cascades are marked (cetuximab, panitumumab, trastuzumab, erlotinib, gefitinib, lapatinib, perifosine, sorafenib, vemurafenib, dabrafenib, selumetinib, trametinib, everolimus, temsirolimus). © 2017 S. Karger AG, Basel

Underlying Mechanisms for Distant Metastasis - Molecular Biology Visc Med 2017;33:11-20 - DOI:10.1159/000454696 Fig. 3. cMet signaling and its influence on the metastatic cascade. HGF binds to the growth factor receptor cMet and activates downstream SHC, PI3K, STAT3/5, C-SRC, SHP2, PCLγ, GRB2, and SOS. This leads to the activation of RAS/RAF, RAS/RAC1m, FAK, and Akt/mTOR, and as a consequence to enhanced tumor proliferation, migration, invasion, EMT, cell survival, and angiogenesis. cMet is targetable by using the receptor antibodies rilotumumab or onartuzumab or the multikinase inhibitor foretinib. © 2017 S. Karger AG, Basel

Underlying Mechanisms for Distant Metastasis - Molecular Biology Visc Med 2017;33:11-20 - DOI:10.1159/000454696 Fig. 4. Wnt signaling and its influence on the metastatic cascade. Wnt ligand binding leads to the inhibition of the destruction complex and consequently to the nucleic accumulation of β-catenin which drives Wnt gene expression. NSAIDs such as sulindac or celecoxib, the antibiotic calcimycin, and the anthelminthic niclosamide target β-catenin-dependent gene transcription. © 2017 S. Karger AG, Basel